ILUMETRI

This brand name is authorized in Austria, Estonia, Spain, France, Croatia, Ireland, Lithuania, Netherlands, Poland, Romania, United Kingdom

Active ingredients

The drug ILUMETRI contains one active pharmaceutical ingredient (API):

1 Tildrakizumab UNII DEW6X41BEK - TILDRAKIZUMAB

Tildrakizumab is a humanized IgG1/k monoclonal antibody that specifically binds to the p19 protein subunit of the interleukin-23 (IL-23) cytokine without binding to IL-12 and inhibits its interaction with the IL-23 receptor. Tildrakizumab inhibits the release of proinflammatory cytokines and chemokines. Read about Tildrakizumab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ILUMETRI Solution for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L04AC17		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AC Interleukin inhibitors
Discover more medicines within L04AC17

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1780130, 1780488
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1181323001
Country: FR	Base de données publique des médicaments	Identifier(s): 69596271
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 364267, 367558
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1086234, 1086387
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 198293
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100411378
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W66238001, W66238002